Cell Therapy Market Size to Capture USD 44.39 Billion by 2034

Cell Therapy Market Size, Shares and Advantages

The global cell therapy market size was estimated at US$ 4.79 billion in 2023 and is projected to grow to US$ 44.39 billion by 2034, rising at a compound annual growth rate (CAGR) of 22.69% from 2024 to 2034. The focus on developing therapeutics for rare diseases is driving the market growth.

Unlock Infinite Advantages: Subscribe to Annual Membership

Major Key Insights of the Cell Therapy Market

• North America dominated the market share by 59% in 2023.
• Asia Pacific is expected to grow at a significant rate during the forecast period.
• By therapy type, the autologous therapy segment dominated the cell therapy market in 2023.
• By therapeutic area, the oncology segment held the largest share of the market in 2023.

Cell Therapy Market: Novel Therapies

The delivery of chosen, modified, or changed cells outside of the body for the purpose of treating or preventing illness is known as cell therapy. With intriguing and developing potential for therapeutic use, cell therapy is a field on the rise. The manufacturing and culturing procedures must develop before these medicines may be used commercially, which usually entails drastically scaling up and automating to match the clinical demand. Over the past twenty years, research at government and university institutions throughout the globe has substantially advanced our knowledge of cell treatments. Different cell types will be researched for possible uses and developed into treatments as innovative cell therapies while the study is still in its early stages.

How can AI Improve the Cell Therapy Market?

There are benefits and drawbacks to using AI in cell therapy. AI technology integration may save costs, streamline logistics, and increase production accuracy and efficiency. AI may also be used to forecast treatment outcomes, track the course of therapy, and identify people who would benefit from it. Furthermore, work is still to be done on the validation of AI-based judgments and the integration of AI systems into current production workflows.

For instance,

• In January 2023, to accelerate the development of innovative cell treatments, CellVoyant, a biotechnology firm founded on artificial intelligence (AI) and spun out of the University of Bristol, acquired £7.6 million in early investment. In a news statement dated January 16, 2024, it was said that Octopus Ventures led the investment round, with participation from Horizon Ventures, Verve Ventures, and Air Street Capital.

Top Companies in the Cell Therapy Market

• Novartis AG
• 2seventy Bio Inc.
• Anterogen Co., Ltd.
• Johnson & Johnson Services, Inc
• Astellas Pharma Inc.
• M Aurion Biotech
• EDIPOST
• Atara Biotherapeutics
• JCR Pharmaceuticals Co., Ltd.
• S. BIOMEDICS
• Holostem Terapie Avanzate S.r.l
• Bristol-Myers Squibb Company
• JW Therapeutics
• Nkarta, Inc.
• Gilead Sciences, Inc.

Pipeline of 2seventy Bio in the Cell Therapy Market

Pipeline of Astellas in the Cell Therapy Market

Stem Cell Applications Drive the Cell Therapy Market

Adult bone marrow stem cells produce a variety of growth factors that enable them to differentiate into the kind of cells required for heart and blood vessel repair. With the use of stem cells, it is possible to stimulate the production of new, healthy skin tissue, boost collagen synthesis, hasten the growth of hair after haircuts or hair loss, and replace damaged or scarred tissue with freshly produced, healthy tissue. Adult stem cells injected into the brain can help regenerate new brain synapses, neurons, and cells after brain damage or cognitive impairment in illnesses such as Parkinson's and Huntington's. The use of stem cells in treating severe and debilitating autoimmune illnesses gives new hope. This therapy may be beneficial for patients with pain related to spinal diseases, orthopedic concerns, and sports injuries. 

High-Cost Restraint the Cell Therapy Market

Cellular and gene therapy are two of the priciest therapies currently offered. Cell treatments are expensive, usually costing more than $400,000 USD and often more than $1 million USD per patient, and there are technological issues that raise questions about their accessibility and affordability for patients, payers, and healthcare systems both domestically and abroad. Budgets for healthcare may also be strained by the expense of cell treatment, forcing governments and insurance companies to make tough decisions about how best to distribute funds and cover different products. The costs involved in producing and administering cell therapy are one factor contributing to its high cost. Specialized equipment, trained personnel, and strict quality control systems could be required for each of these processes.

CAR T-Cell Therapy: The Cell Therapy Market’s Future

One of the newest and most promising treatments for blood cancer is CAR-T cell therapy. Through the activation of the immune system, these medicines support the fight against cancer. Future cancer treatments might greatly benefit from CAR T-cell therapy because of its many advantages. CAR T cells have proven to be a successful treatment for several cancers, particularly blood cancers like leukemia and lymphoma. The specific antigen that is present in malignant cells is the target of CAR T cells. This modification reduces harmful effects and harm to healthy tissues to a minimum. The purpose of CAR T cells is to multiply and persist throughout the body. This suggests that they could offer long-term protection against the cancer coming back.

For instance,

• In June 2024, Cytiva unveiled its Sefia next-generation manufacturing platform to streamline the production of chimeric antigen receptor T (CAR T) cell therapies and other cell-based medicines for pharmaceutical firms and larger healthcare providers at a competitive price. Tecartus® (brexucabtagene autoleucel) and Yescarta® (axicabtagene ciloleucel), two well-known CAR T therapies, were developed by Kite, a Gilead company in partnership with Cytiva. This collaboration allowed Kite to use technology and manufacturing capabilities to build Sefia.

The Autologous Therapy Segment Dominated in 2023

By therapy type, the autologous therapy segment dominated the cell therapy market in 2023. Autologous cell therapy, with applications in immuno-oncology and regenerative medicine, is a fast-expanding therapeutic method. Autologous methods have the important benefit of reducing the danger of immunological rejection in patients and fostering long-term recovery. The ability to tailor autologous cell treatment to the specific requirements of each patient is an additional advantage. Thus far, this type of treatment has shown effective in treating burns and pressure ulcers, promoting wound healing, reducing chronic inflammation, and improving postoperative healing—all while bioengineering skin replacements.

For instance,

• In April 2024, Aspen Neuroscience, Inc. reported that the first patient in the Phase 1/2a open-label clinical trial ASPIRO has received a dose. The trial's goal is to evaluate the safety and tolerability of ANPD001, an autologous therapy that replaces dopaminergic neurons in the brains of patients suffering from moderate to severe Parkinson's disease (PD). A private biotechnology business called Aspen Neuroscience is creating customized regenerative medicine.

The Oncology Segment Dominated the Market

By therapeutic area, the oncology segment held the largest share of the cell therapy market in 2023. Cell therapy is essential to our goal of making cancer no longer a leading cause of death due to the disease's rising incidence. In cell-mediated immunity and T-cell genetic modification techniques, T-cells are crucial. Therapeutic promise for preventing tumor formation has been demonstrated by CAR-T cell and TCR-T cell treatments, which have shown promising clinical outcomes in clinical studies.

For instance,

• In May 2024, the Stanford Medicine Center became the first center in the nation to treat a patient who was suffering from metastatic melanoma by using FDA-approved cell-based therapy. It creates an opportunity for treating patients with advanced melanoma who have developed resistance to immunotherapies. It is the first cell-based therapy that was approved by the FDA for solid tumors.

In May 2024, Elicera Therapeutics is about to begin CARMA, its first clinical CAR T-cell research, with the goal of gathering vital information for both the immune-boosting iTANK technology and its flagship CAR T-cell candidate, ELC-301. The purpose of the two-part CARMA phase I/IIa trial is to evaluate the safety and effectiveness of ELC-301 in patients with advanced malignancies associated with B cells.

Cancer Research Drives the North America’s Market

By region, North America dominated the cell therapy market share by 59% in 2023. North America is considered technologically advanced, with advanced healthcare infrastructure and research centers equipped with advanced systems. With time, the region has focused on providing better therapeutics and medicines to treat illness with the help of key organizations and governments. These factors have significantly contributed to the growth of the market in this region. The major countries that have contributed to this growth are the U.S. and Canada.

The U.S. holds the largest share of the cell therapy market in North America, and one of the main reasons for that is the growing prevalence of cancer. The U.S. is among the top countries with a large number of cancer cases. Cell therapy has proven to be highly useful in conducting cancer research and cancer therapeutics. With the growing number of cancer cases, the country is heavily focused on cancer research.

In order to guarantee that Canada stays at the forefront of innovation and research into new technologies, the government of Canada is committed to investing in these areas. The Strategic Science Fund provides up to $171.6 million in support for independent scientific and research institutions, as announced by the Minister of Health. As announced in December 2023, the money will assist five groups in Ottawa and was granted following a new open, merit-based, competitive procedure that was guided by the recommendations of an impartial expert review panel.

Government Investments Drive Asia Pacific’s Growth

By region, Asia Pacific is expected to grow at a significant rate during the forecast period. Asia Pacific’s cell therapy market is growing due to multiple factors. One of the major factors is government initiatives. The governments of China, India, and Japan are majorly contributing to the market. To this date, various cell therapies have been approved in the Asia Pacific, which are listed in the table, and more research is going on to develop new cell therapies.

For instance,

• In April 2024, at the Indian Institute of Technology (IIT) Bombay in Mumbai, the Governor of Maharashtra, Shri Ramesh Bais, witnessed the nation's first homegrown anti-cancer CAR-T cell treatment being introduced by the President of India, Smt. Droupadi Murmu.

India is becoming a hub of cancer due to smoking, environmental factors, and consumption of carcinogens. The lack of treatment options is leading to numerous cancer-related deaths. To Mitigate this, the Indian Government has taken various initiatives to utilize cell therapies for the treatment of cancer.

For instance,

Recent Developments in the Cell Therapy Market

• In April 2024, for the manufacturing of CAR T cell treatments, Bristol Myers Squibb and Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to the production of cell therapies at the clinical and industrial scale, announced a global capacity reserve and supply agreement. Up to $380 million in milestone and upfront payments are part of the transaction's worth.
• In February 2024, the clinical-stage biopharmaceutical company Autolus Therapeutics plc, which is developing next-generation programmed T-cell therapies, and BioNTech SE, which is leading the way in next-generation immunotherapy and developing novel therapies for cancer and other serious diseases, have announced a strategic collaboration to move both companies' autologous CAR-T programs closer to commercialization, subject to regulatory authorizations. The firms signed into a licensing and option agreement as well as a securities purchase agreement in line with their strategic partnership. BioNTech consents to give Autolus $200 million in funding.
• In February 2024, For the purpose of launching its life-saving cell therapy technologies in the US for important cancer studies and potential commercial supply, AstraZeneca committed $300 million to a state-of-the-art facility in Rockville, MD. With an initial focus on producing T-cell treatments to allow for global clinical trials, more than 150 new, highly qualified employment will be created. The website may gradually broaden its scope to include help for more illness categories.

Segments Covered in the Report

By Therapy Type

• Autologous Therapies
  • Stem Cell Therapies
    • BM, Blood, & Umbilical Cord-derived Stem Cells
    • Adipose-Derived Cells
    • Others
  • Non-Stem Cell Therapies
    • T-Cell Therapies
      • CAR T Cell Therapy
      • T Cell Receptor (TCR)-based
    • Others
• Allogeneic Therapies
  • Stem Cell Therapies
    • Hematopoietic Stem Cell Therapies
    • Mesenchymal Stem Cell Therapies
  • Non-Stem Cell Therapies
    • Keratinocytes & Fibroblast-based Therapies
    • Others

By Therapeutic Area

• Oncology
• Musculoskeletal Disorders
• Cardiovascular Disease (CVD)
• Dermatology
• Others

By Region

• North America
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait